World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester ( p> Dr Marcus Cooke Senior lecturer in...)

World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester

Dr Marcus Cooke, Senior lecturer in the Radiation and Oxidative Stress Section at the University of Leicester, added: "It is a really good feeling to be involved in a project looking at oxidative stress, that can make such an enormous difference to a person's quality of life.

"I think that we will see an increasing use of biomarkers of oxidative stress to support clinical decisions."

Dr Cooke said that idiopathic pulmonary haemosiderosis is a devastating condition. Characteristic of this condition is the accumulation of protein-bound iron in the lungs, a consequence of repeated bleeding in the lungs, coupled with inflammation and fibrosis. Ultimately this condition is usually fatal. Treatment to prevent the lung damage and prevent anaemia is a combination of corticosteroids and iron supplement.

Both chronic inflammation, and the presence of iron, released following bleeding into the lungs, can lead to a condition known as oxidative stress. Oxidative stress occurs when the production of free radicals, highly reactive chemicals, outweighs antioxidant defences. This leads to a great deal of damage to cells, and in particular DNA, the cell's 'blueprint', and is likely to be responsible for the fibrosis, as the lungs try to repair the damage done by free radicals.

"In order to establish whether oxidative stress was indeed associated with episodes of bleeding into the lungs, we measured a biomarker of oxidative stress, and a marker of damage to DNA specifically, in urine.

"We noted that levels of oxidative stress increased significantly following every bleed. With this in mind, and on the basis that antioxidants can potentially boost the body's natural defences, we began the patient on a course of the antioxidant drug N-acetyl cysteine. Five months into antioxidant therapy, the patient remains clinically well, and on a reduced dose of corticosteroids."

NOTE TO NEWSDESK: For more information, please contact:

Prof. Jona
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
3. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
4. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
7. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
8. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
9. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
10. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
11. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Post Your Comments:

( p> Dr Marcus Cooke Senior lecturer in...)World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester,Health